For millions who live with the interrupted rhythms of sleep apnea, the search for relief has long circled back to a single, difficult prescription: lose weight. Now, a class of medications already reshaping how medicine approaches obesity — GLP-1 drugs like Zepbound — appears to offer something rarer than a new treatment: a single intervention addressing two deeply entangled conditions at once. The early evidence is not yet a verdict, but it opens a meaningful question about whether the tools we use to fight obesity might quietly be healing more than we knew.